VYNE Therapeutics Inc. (MNLO) [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16
	10-K	10-K	10-K	10-K	10-K	10-K	10-K
Assets
Cash and equivalents	30.9	42.3	57.6	43.8	49.5	10.2	4.0
Short-term investments			1.0	28.3	86.7	49.3	26.9
Accounts receivable, net	0.2	7.6	15.8	0.1		0.8
Inventories			7.4	1.4
Other current assets	7.2	13.4	5.4	2.8	3.3	3.6	0.6
Total current assets	38.3	63.2	87.3	76.4	139.5	63.9	31.5
Property, plant, and equipment, net		0.4	0.6	2.9	0.1	0.0	0.0
Long-term investments						3.0	10.4
Other fixed assets				0.2	0.3		0.1
Total assets	40.8	67.0	93.7	81.2	139.9	66.9	42.1

Accounts payable	2.4	6.5	4.8	19.4	3.3	2.5	1.5
Accrued expenses	4.4	8.6	11.5	5.2	6.3	3.6	0.6
Short-term debt	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred revenues						1.8	1.8
Other current liabilities			5.5	4.7
Total current liabilities	6.8	15.1	21.8	29.3	9.5	7.8	3.9
Long-term debt			33.2	32.7
Other liabilities	2.6	3.3	1.3	1.5	0.0	6.8	8.6
Total liabilities	9.3	18.4	56.2	63.6	9.6	14.6	12.5

Shareholders' equity [+]	31.4	48.6	37.5	17.6	130.4	52.3	29.6
Paid-in capital	693.9	688.2	603.7	328.2	241.1	2.2	0.7
Retained earnings	-662.7	-639.5	-566.2	-310.6	-110.6	-59.2	-30.1
Tangible shareholders' equity	31.4	48.6	37.5	17.6	130.4	52.3	29.6